{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:53:08Z","timestamp":1791910388723,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacc.2025.08.028","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:09:48Z","timestamp":1756282188000},"page":"1823-1839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-9414","authenticated-orcid":false,"given":"John W.","family":"Ostrominski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.08.028_bib1","series-title":"World Obesity Atlas 2024","year":"2024"},{"key":"10.1016\/j.jacc.2025.08.028_bib2","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: the DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.028_bib3","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jacc.2017.09.1111","article-title":"Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF","volume":"70","author":"Tsujimoto","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.028_bib4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","article-title":"The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF","volume":"6","author":"Savji","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.028_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCULATIONAHA.120.047019","article-title":"Temporal trends in prevalence & prognostic implications of comorbidities among patients with acute decompensated heart failure: the ARIC study community surveillance","volume":"142","author":"Pandey","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.028_bib7","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jacc.2025.08.028_bib8","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.028_bib9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.028_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0939-4753(03)80018-2","article-title":"Role of the natriuretic peptide system in lipogenesis\/lipolysis","volume":"13","author":"Dess\u00ec-Fulgheri","year":"2003","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2025.08.028_bib11","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2013.03.038","article-title":"Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile","volume":"62","author":"Neeland","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.028_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.028_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2015.11.049","article-title":"Acute metabolic influences on the natriuretic peptide system in humans","volume":"67","author":"Arora","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.028_bib14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/HYPERTENSIONAHA.118.11081","article-title":"Natriuretic peptides in cardiovascular and metabolic crosstalk: implications for hypertension management","volume":"72","author":"Jordan","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.08.028_bib15","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1016\/j.jacc.2021.04.055","article-title":"Natriuretic peptide deficiency in obese individuals: mechanistic insights from healthy organ donor cohort","volume":"77","author":"Parcha","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.028_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jchf.2020.08.015","article-title":"Soluble neprilysin and corin concentrations in relation to clinical outcome in chronic heart failure","volume":"9","author":"Gommans","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib17","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1161\/CIRCULATIONAHA.105.555573","article-title":"Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study","volume":"112","author":"Das","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.028_bib18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjhf\/hfp099","article-title":"Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma","volume":"11","author":"Palmer","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcmg.2020.07.022","article-title":"Body composition, natriuretic peptides, and adverse outcomes in heart failure with preserved and reduced ejection fraction","volume":"14","author":"Selvaraj","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.08.028_bib20","first-page":"99","article-title":"Lean body mass in obesity","volume":"7","author":"Forbes","year":"1983","journal-title":"Int J Obes"},{"key":"10.1016\/j.jacc.2025.08.028_bib21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40520-023-02427-6","article-title":"Higher abdominal adiposity is associated with higher lean muscle mass but lower muscle quality in middle-aged and older men and women: The Framingham Heart Study","volume":"35","author":"Raghupathy","year":"2023","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.jacc.2025.08.028_bib22","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacc.2025.08.028_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics. An updated 2024 report from the Heart Failure Society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib24","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.028_bib25","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2003.10.066","article-title":"Obesity and suppressed B-type natriuretic peptide levels in heart failure","volume":"43","author":"Mehra","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.028_bib26","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archinte.167.4.400","article-title":"Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro\u2013brain natriuretic peptide in patients with acute dyspnea","volume":"167","author":"Bayes-Genis","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2025.08.028_bib27","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamacardio.2018.2568","article-title":"Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial","volume":"3","author":"Myhre","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.08.028_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of sacubitril\/valsartan on n-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib29","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.028_bib30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.028_bib31","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.028_bib32","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.028_bib33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCHEARTFAILURE.112.972794","article-title":"Baseline characteristics of patients in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"6","author":"Shah","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.028_bib37","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014new insights into regional variation","volume":"376","author":"de Danus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.028_bib38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ejhf.274","article-title":"Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-PRESERVE Study","volume":"17","author":"Jhund","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib39","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jchf.2022.08.007","article-title":"Influence of NT-proBNP on efficacy of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"10","author":"Myhre","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib41","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.08.028_bib42","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jacc.2024.11.007","article-title":"Systolic blood pressure and pulse pressure in heart failure: pooled participant-level analysis of 4 trials","volume":"85","author":"Lu","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.028_bib43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2024.08.009","article-title":"Natriuretic peptides, kidney function, and clinical outcomes in heart failure with preserved ejection fraction","volume":"13","author":"Neuen","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.028_bib44","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.124.072156","article-title":"Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting","volume":"151","author":"Reddy","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.028_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015738","article-title":"Highest obesity category associated with largest decrease in N-terminal pro-B-type natriuretic peptide in patients hospitalized with heart failure with preserved ejection fraction","volume":"9","author":"Vaishnav","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.08.028_bib46","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Risk Factors Collaborators","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.028_bib47","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1161\/CIR.0000000000001307","article-title":"Risk-based primary prevention of heart failure: a scientific statement from the American Heart Association","volume":"151","author":"Khan","year":"2025","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2025.08.028_bib48","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.2337\/dc24-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.08.028_bib49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725074935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725074935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T01:23:05Z","timestamp":1766193785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725074935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":49,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0735109725074935"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.028","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}